NICE thresholds now sit at £25,000 to £35,000 per quality-adjusted life year following a major policy update in April 2026. This change marks an important shift in how the NHS assesses the value of new medicines and health technologies.

Policy Background

For 26 years the core cost-effectiveness threshold remained unchanged despite advances in medicine and rising treatment costs. The government has now increased the range that NICE can apply in technology appraisals. The institute already recommends 91 percent of evaluated medicines, roughly 70 per year. Officials expect the new NICE thresholds to support approval of three to five additional treatments annually.

Impact on Market Access

Companies will notice immediate differences in launch planning. Treatments that previously required substantial discounts to fall below the old £30,000 upper limit now stand a stronger chance of routine NHS funding. This adjustment reduces the commercial pressure to offer large Patient Access Scheme discounts and improves net revenue forecasts for many assets.

England ranked sixth out of 36 European countries in the 2024 EFPIA WAIT report for medicine availability. The updated NICE thresholds should help maintain or improve this position by aligning the formal value placed on health gains more closely with current economic conditions.

Changes to Economic Evaluation

Analysts must now present results using both £25,000 and £35,000 per QALY when calculating expected net health benefit. This dual approach brings greater transparency, especially when severity modifiers or health inequality considerations apply. Cost-effectiveness acceptability curves and incremental cost-effectiveness ratios require updating to reflect the new range.

Modellers should also prepare for the forthcoming adoption of the EQ-5D-5L value set. Although this will follow the threshold change by several months, the combined effect will influence quality-adjusted life year estimates across many disease areas.

Implications for Industry Strategy

Pharmaceutical teams should review late-stage pipeline assets against the revised NICE thresholds. Assets previously considered marginal now deserve fresh analysis. Early scientific advice meetings with NICE become even more valuable to align evidence plans with the updated methods.

• Re-evaluate pricing assumptions for UK launches
• Strengthen demonstration of broader system benefits and cost offsets
• Consider requesting re-appraisal where significant new clinical data exist

System-wide Considerations

The NHS will face additional budget pressure from the extra approvals. Integrated care systems and specialised commissioning teams need robust horizon scanning and innovative contracting approaches to manage the introduction of these medicines. NICE continues to stress that recommendations depend on clinical evidence as well as cost.

Importantly, the change applies only to standard technology appraisals. Highly specialised technologies for ultra-rare diseases retain their separate £100,000 to £300,000 per QALY thresholds for now.

Conclusion

The rise in NICE thresholds represents a measured response to long-standing calls for updated value assessment in the NHS. By placing a higher explicit value on health gains, the policy seeks to improve patient access while supporting the life sciences sector. Success will depend on careful implementation and ongoing evaluation of both access metrics and budgetary impact.

Healthcare leaders and market access professionals should monitor the first wave of decisions under the new framework. These outcomes will shape UK strategy for years to come.